Molecular Medicine

, Volume 17, Issue 5–6, pp 391–396 | Cite as

Inhibition of HDAC Activity by ITF2357 Ameliorates Joint Inflammation and Prevents Cartilage and Bone Destruction in Experimental Arthritis

  • Leo A B Joosten
  • Flavio Leoni
  • Sajeda Meghji
  • Paolo Mascagni
Review Article


Inhibition of histone deacetylases (HDAC) has been shown to modulate gene expression and cytokine production after stimulation with several stimuli. In the present study, the antiinflammatory effect of a potent HDACi, ITF2357, was explored in different experimental models of arthritis. In addition, the bone protective effect of ITF2357 was investigated invitro. Treatment of acute arthritis (Streptococcus pyogenes cell wall (SCW) arthritis) with ITF2357 showed that joint swelling and cell influx into the joint cavity were reduced. Furthermore, the chondrocyte metabolic function was improved by treatment of ITF2357. The production of proinflammatory cytokines by synovial tissue was reduced after ITF2357 treatment. To examine the effect of HDAC inhibition on joint destruction, ITF2357 was applied to both rat adjuvant arthritis and mouse collagen type II arthritis. ITF2357 treatment both ameliorates the severity scores in arthritis models and prevents bone destruction. In an in vitro bone destruction assay, ITF2357 was highly effective at a dose of 100 nmol/L. In conclusion, inhibition of HDAC prevents joint inflammation and cartilage and bone destruction in experimental arthritis.


  1. 1.
    Khan N, et al. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409:581–9.CrossRefGoogle Scholar
  2. 2.
    Gerstner T, Bell N, Konig S. (2008) Oral valproic acid for epilepsy—long-term experience in therapy and side effects. Expert. Opin. Pharmacother. 9:285–92.CrossRefGoogle Scholar
  3. 3.
    Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89:1358–67.CrossRefGoogle Scholar
  4. 4.
    Marks PA, et al. (2001) Histone deacetylases and cancer: causes and therapies. Nature Rev. Cancer. 1:194–202.CrossRefGoogle Scholar
  5. 5.
    Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452–8.CrossRefGoogle Scholar
  6. 6.
    O’Connor OA, et al. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoy-lanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24:166–73.CrossRefGoogle Scholar
  7. 7.
    Richon VM, Zhou X, Rifkind RA, Marks PA. (2001) Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (saha) for the treatment of cancers. Blood Cells Mol. Dis. 27:260–4.CrossRefGoogle Scholar
  8. 8.
    Park JH, et al. (2004) Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. 10:5271–81.CrossRefGoogle Scholar
  9. 9.
    Leoni F, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. U. S. A. 99:2995–3000.CrossRefGoogle Scholar
  10. 10.
    Matalon S, et al. (2010) The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4+ T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J. Acquir. Immune Defic. Syndr. 54:1–9.CrossRefGoogle Scholar
  11. 11.
    Reddy P, et al. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl. Acad. Sci. U. S. A. 101:3921–6.CrossRefGoogle Scholar
  12. 12.
    Reilly CM, et al. (2004) Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J. Immunol. 173:4171–8.CrossRefGoogle Scholar
  13. 13.
    Glauben R, et al. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176:5015–22.CrossRefGoogle Scholar
  14. 14.
    Leoni F, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of proinflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1–15.CrossRefGoogle Scholar
  15. 15.
    Leng C, et al. (2006) Reduction of graft-versus-host disease by histone deacetylase inhibitor suberony-lanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp. Hematol. 34:776–87.CrossRefGoogle Scholar
  16. 16.
    Shein NA, et al. (2009) Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 23:4266–75.CrossRefGoogle Scholar
  17. 17.
    Glauben R, et al. (2008) Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 57:613–22.CrossRefGoogle Scholar
  18. 18.
    Kawabata T, et al. (2010) Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res. Ther. 12:R133.CrossRefGoogle Scholar
  19. 19.
    Grabiec AM, et al. (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 184:2718–28.CrossRefGoogle Scholar
  20. 20.
    Rosato RR, et al. (2003) Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2:1273–84.PubMedGoogle Scholar
  21. 21.
    Choo QY, et al. (2010) Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaBp65 nuclear accumulation in human rheumatoid arthritis synovial fibro-blastic E11 cells. Rheumatology. 49:1447–60.CrossRefGoogle Scholar
  22. 22.
    Nasu Y, et al. (2008) Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage. 16:723–32.CrossRefGoogle Scholar
  23. 23.
    Nishida K, et al. (2004) Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 50:3365–76.CrossRefGoogle Scholar
  24. 24.
    Dinarello CA, Fossati G, Mascagni P. (2011) Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol. Med. 17:333–352.CrossRefGoogle Scholar
  25. 25.
    Saouaf SJ, et al. (2009). Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87:99–104.CrossRefGoogle Scholar
  26. 26.
    Saklatvala J, Dingle JT. (1980) Identification of catabolin, a protein fro synovium which induces degradation of cartilage in organ culture. Biochem. Biophys. Res. Commun. 96:1225–31.CrossRefGoogle Scholar
  27. 27.
    Abdollahi-Roodsaz S, et al. (2009) Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation. Am. J. Pathol. 175:2004–13.CrossRefGoogle Scholar
  28. 28.
    Kuiper S, et al. (1998) Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine. 10:690–702.CrossRefGoogle Scholar
  29. 29.
    Joosten LA, et al. (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J. Immunol. 163:5049–55.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Joosten LA, et al. (2008) T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17. Arthritis Rheum. 58:98–108.CrossRefGoogle Scholar
  31. 31.
    Joosten LA, et al. (2003) Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J. Immunol. 171:6145–53.CrossRefGoogle Scholar
  32. 32.
    Joosten LA, et al. (2008) Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. Proc. Natl. Acad. Sci. U. S. A. 105:9017–22.CrossRefGoogle Scholar
  33. 33.
    Lin HS, et al. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150:862–72.CrossRefGoogle Scholar
  34. 34.
    Zwerina J, et al. (2007) TNF-induced structural joint damage is mediated by IL-1. Proc. Natl. Acad. Sci. U. S. A. 104:11742–7.CrossRefGoogle Scholar
  35. 35.
    Polzer K, et al. (2010) Interleukin-1 is essential for systemic inflammatory bone loss. Ann. Rheum. Dis. 69:284–90.CrossRefGoogle Scholar
  36. 36.
    Gowen M, Mundy GR. (1986) Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J. Immunol. 136:2478–82.PubMedGoogle Scholar
  37. 37.
    Kim HN, et al. (2009) Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. Eur. J. Pharmacol. 623:22–9.CrossRefGoogle Scholar
  38. 38.
    Nakamura T, et al. (2005) Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J. Immunol. 175:5809–16.CrossRefGoogle Scholar
  39. 39.
    Young DA, et al. (2005) Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res. Ther. 7:R503–12.CrossRefGoogle Scholar
  40. 40.
    Wang X, Song Y, Jacobi JL, Tuan RS. (2009) Inhibition of histone deacetylases antagonized FGF2 and IL-1beta effects on MMP expression in human articular chondrocytes. Growth Factors. 27:40–9.CrossRefGoogle Scholar
  41. 41.
    Higashiyama R, et al. (2010) Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis. Mod. Rheumatol. 20:11–7.CrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  • Leo A B Joosten
    • 1
    • 2
  • Flavio Leoni
    • 3
  • Sajeda Meghji
    • 4
  • Paolo Mascagni
    • 3
  1. 1.Department of Medicine (463)Radboud University Nijmegen Medical CenterGA, Nijmegenthe Netherlands
  2. 2.Nijmegen Institute of Infection, Inflammation and Immunity (N4i)Radboud University Nijmegen Medical CentreNijmegenthe Netherlands
  3. 3.Research CenterItalfarmaco, SpACinisello Balsamo, MilanItaly
  4. 4.UCL Eastman Dental InstituteLondonUK

Personalised recommendations